Hong Kong Stock Movement: WUXI XDC's performance shows strong growth of 10.33%, UBS maintains "Buy" rating to support stock price rise

Hong Kong Stock Movement WUXI XDC rose 10.33%. Based on recent key news: On March 24, WUXI XDC announced its 2025 performance, with revenue of 5.944 billion yuan, a year-on-year increase of 46.7%; gross profit of 2.139 billion yuan, up 72.5%. Net profit was 1.48 billion yuan, an increase of 38.4%. The strong performance drove the stock price up. Source: Zhitong Finance On March 24, UBS released a report maintaining a "Buy" rating for WUXI XDC, with a target price of HKD 90.4. The company's Singapore factory is set to commence production in the first half of 2026, further enhancing capacity. Source: UBS On March 23, WUXI XDC announced the integration of Dongyao Pharmaceutical's Suzhou factory, expanding its capacity and enhancing global service capabilities. This move is seen by the market as a strategic expansion, boosting investor confidence. Source: Zhitong Finance. The biopharmaceutical industry is experiencing strong growth, with robust market demand. Stocks with High Trading Volume in the Industry WuXi AppTec rose 10.13%. Based on recent news, On March 23, WuXi AppTec released its 2025 performance report, showing operating revenue of 45.456 billion yuan, a year-on-year increase of 15.8%; net profit attributable to shareholders was 19.195 billion yuan, a year-on-year increase of 105.2%. This news boosted market confidence, driving the stock price up. On March 24, Goldman Sachs released a research report indicating that WuXi AppTec's net profit for the fourth quarter of 2025, according to non-International Financial Reporting Standards, grew by 36.6% year-on-year, and gave a "Buy" rating with a target price of HKD 144.6. This rating further propelled the stock price upward. On March 24, UBS released a research report raising WuXi AppTec's target price to HKD 154.1 and maintained a "Buy" rating. UBS believes the company's profit margins are stable, and the quality of order backlog is high, further enhancing investor confidence. The overall industry is performing well, with significant capital inflows. WuXi Biologics rose 4.38%. Based on recent news, On March 23, WuXi AppTec released its 2025 performance, with operating revenue of 45.456 billion yuan, a year-on-year increase of 15.8%; net profit attributable to shareholders was 19.195 billion yuan, a year-on-year increase of 105.2%. This strong performance boosted market confidence, driving the stock price up. On March 23, WuXi AppTec announced a cash dividend of 15.7927 yuan (tax included) for every 10 shares, further enhancing investor confidence in the company's future development, leading to a rise in stock price. On March 24, Zhitong Finance reported that WuXi AppTec's stock rose over 6% after the earnings report, and as of the time of publication, it was up 6.33%, trading at HKD 109.2, with a trading volume of HKD 173 million. The market holds an optimistic outlook on the company's future, driving the stock price to continue rising. The demand in the CXO industry is recovering, and WuXi AppTec's performance is impressive JingTai Holdings rose 1.46%, with a transaction volume reaching HKD 427 million, and there have been no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks ranked at the top of the industry by market capitalization Crown Bioscience rose 4.08%. Based on recent key news: On March 23, the closure of the Strait of Hormuz affects energy supply, and UBS believes that Chinese companies are likely to become potential beneficiaries, with Crown Bioscience having potential opportunities in gaining global market share. Source: Zhitong Finance On March 23, Crown Bioscience's collaboration with Eli Lilly received a USD 200 million investment, enhancing its high-end CDMO business capabilities and attracting more collaborations with large pharmaceutical companies. Source: Zhitong Finance. The risk of supply chain disruptions in petrochemical products is rising